151
report
Framing the Issues: Building Securitization Markets in Africa to Advance the SDGs
Despite their promise, securitization markets are under-developed in many developing and emerging m
arket countries, including across the continent of Africa, where the SDG financing gap is the widest.
+ Read More
report
Global Opportunity Index 2021 White Paper
The Global Opportunity Index assesses countries' attractiveness to international investors using a
combination of economic, financial, institutional, and regulatory factors., Find Your Country Using the Interactive Map
,
+ Read More
report
Accelerating Securitization in Africa to Finance the SDGs: Future Flow Securitizations
The sustainable development goals (SDGs) set an ambitious development agenda to reduce poverty by 2
030 and an equally ambitious agenda to finance them.
+ Read More
report
Request for Proposals: Misophonia
The Misophonia Research Fund is pleased to release the 2023 Request for Proposals.
panel
Walking the Talk: Investing in the Future of Black Banks, Entrepreneurship, and Opportunity
The COVID-19 pandemic and subsequent economic downturn have had a disproportionate effect on Bla
ck businesses and entrepreneurs across the country.
+ Read More
podcast episode
Ep. 123: Priorities, with Anheuser-Busch’s Michel Doukeris
“In protecting our business, we are not talking about protecting Anheuser-Busch’s business, but ev
erybody in the chain that was relying on AB to maintain their business continuity.
+ Read More
panel
Agents of Change: The Future of Capital Markets (Invite only)
Over the past year and a half, markets have navigated through a recession, a deadly pandemic, an
d social upheaval. Companies have shifted business practices, from moving to a remote workforce to putting greater emphasis on corporate responsibility.
+ Read More
panel
Gaps Amid the Progress: Uncovering Blind Spots that Persist in Patient Centric Research (Invite only)
This workshop brings together thought leaders from the FasterCures community to identify persist
ent gaps preventing full engagement of patients in R&D and post-drug-approval efforts.
+ Read More